Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Study on the Tolerability, Safety and Efficacy of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors

NCT07073534 is registered in ClinicalTrials.gov with Shanghai Hengrui Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07073534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07073534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Study on the Tolerability, Safety and Efficacy of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
Lead sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 24, 2025
Completion date
December 31, 2027
Enrollment
203 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients with advanced or metastatic malignant tumors